Search

1. Searching for savings in Medicare drug price negotiations

Author(s):

Cubanski, Juliette, author
Neuman, Tricia, author

Publication:

San Francisco, CA : Henry J. Kaiser Family Foundation, April 2018

Subject(s):

Drug Costs
Medicare Part D -- economics
Negotiating
Prescription Drugs -- economics
United States

2. How does the Trump Administration drug pricing blueprint affect Medicaid?

Author(s):

Young, Katherine, author

Publication:

San Francisco, CA : Henry J. Kaiser Family Foundation, May 2018

Subject(s):

Cost Control
Drug Costs
Medicaid -- economics
Prescription Drugs -- economics
United States
United States.

3. A sense of déjà vu: the debate surrounding state biosimilar substitution laws

Author(s):

Purvis, Leigh, author

Publication:

Washington, D.C. : AARP Public Policy Institute, September 2014

Subject(s):

Biological Products -- economics
Biological Products -- therapeutic use
Biosimilar Pharmaceuticals -- economics
Biosimilar Pharmaceuticals -- therapeutic use
Drug Costs
Drug Substitution
Legislation, Drug
United States
United States. Food and Drug Administration
United States.

4. The Pharmaceutical Industry Must Join America

Publication:

Produced: 22 January 1960

Subject(s):

Drug Industry
Drug Costs
Antipsychotic Agents
Phenothiazines
Hospitals, Psychiatric
Health Policy

Archival Collection:

The Mike Gorman Papers (Profiles in Science)

5. Calculation of potential inflation-indexed rebates for Medicare Part B drugs

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017

Subject(s):

Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
United States
United States. Department of Health and Human Services

6. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017

Subject(s):

Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare Part B -- economics
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

7. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2017

Subject(s):

Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare -- economics
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

8. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017

Subject(s):

Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
Prospective Payment System
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)
Healthcare common procedure coding system

9. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017

Subject(s):

Drug Costs
Drug Industry -- economics
Medicaid -- economics
Pharmaceutical Preparations -- classification
Pharmaceutical Preparations -- economics
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

10. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018

Subject(s):

Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

11. Getting to lower prescription drug prices: the key drivers of costs and what policymakers can do to address them

Author(s):

Waxman, Henry A., author
Corr, Bill, author
Sharp, Jeremy, author
McDonald, Ruth, author
Kenyatta, Kahaari, author

Publication:

[New York, New York] : The Commonwealth Fund, October 2020

Subject(s):

Drug Costs
Prescription Drugs -- economics
Cost Control
Health Policy
United States

12. Medicaid's most costly outpatient drugs

Author(s):

Young, Katherine, author
Rudowitz, Robin, author
Garfield, Rachel, author
Musumeci, MaryBeth, author

Publication:

Menlo Park, CA : Henry J. Kaiser Family Foundation, July 2016

Subject(s):

Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicaid -- economics
Prescription Drugs -- economics
United States

13. How state Medicaid programs are managing prescription drug costs: results from a state Medicaid pharmacy survey for state fiscal years 2019 and 2020

Author(s):

Gifford, Kathleen, author
Winter, Anne, author
Wiant, Linda, author
Dolan, Rachel, author
Tian, Marina, author
Garfield, Rachel, author

Publication:

San Francisco, CA : Henry J. Kaiser Family Foundation, April 2020

Subject(s):

Cost Control
Drug Costs
Medicaid
State Government
United States

14. Drug price increases that exceed inflation are costing Medicare Part D billions

Author(s):

Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, June 2021

Subject(s):

Drug Costs
Inflation, Economic
Medicare Part D -- economics
Medicare Part D -- trends
Prescription Drugs -- economics
United States

15. Prescription drugs: spending, use, and prices

Author(s):

Hayford, Tamara, author
Austin, David, author

Publication:

[Washington, DC] : Congressional Budget Office, January 2022

Subject(s):

Drug Costs
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
United States

16. Paying for drugs in Medicare Part D under current law and under proposals to redesign the program

Author(s):

Baker, Colin, author
Laughery, Scott, author

Publication:

[Washington, DC] : Congressional Budget Office, November 2021

Subject(s):

Cost Control
Drug Costs
Medicare Part D -- organization & administration
United States

17. Estimated changes to employer-sponsored health insurance premiums due to the drug inflation rebate provision of the Build Back Better Act

Author(s):

Simpson, Michael, author
Holahan, John, author

Publication:

Washington, DC : Urban Institute, December 2021

Subject(s):

Drug Costs
Health Benefit Plans, Employee
United States

18. Equilibrium effects of pharmaceutical bundling: evidence from India

Author(s):

Cao, Shengmao, author
Chatterjee, Chirantan, author

Publication:

[Stanford, CA] : Stanford Institute for Economic Policy Research (SIEPR), January 6, 2022

Subject(s):

Drug Combinations
Drug Costs
Economic Competition
Economics, Pharmaceutical
India
United States

19. Competitive bidding in drug procurement: evidence from China

Author(s):

Cao, Shengmao, author
Yi, Xuejie, author
Yu, Chuan, author

Publication:

[Stanford, CA] : Stanford Institute for Economic Policy Research (SIEPR), January 2022

Subject(s):

Competitive Bidding
Drug Costs
Economics, Pharmaceutical
Models, Economic
China
United States

20. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):

Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author

Publication:

Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019

Subject(s):

Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
United States
United States. Food and Drug Administration
Medical Expenditure Panel Survey (U.S.)

21. Drug price moderation in Germany: lessons for U.S. reform efforts

Author(s):

Robinson, James C., author
Ex, Patricia, author
Panteli, Dimitra, author

Publication:

[New York, N.Y.] : The Commonwealth Fund, January 2020

Subject(s):

Drug Costs
Economics, Pharmaceutical
Negotiating
Germany
United States

22. Medicare Part D

Author(s):

Steiner, David J., author

Publication:

[Toronto, Ontario] : Thomson Reuters, 23-December-2019

Subject(s):

Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

23. Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate

Publication:

Washington, DC : United States Government Accountability Office, May 15, 2018

Subject(s):

Drug Costs
Economics, Pharmaceutical
Government Regulation
Medicaid -- economics
United States
United States. Health Resources and Services Administration

24. Drug discount program: federal oversight of compliance at 340B contract pharmacies needs improvement : report to Congressional requesters

Publication:

Washington, DC : United States Government Accountability Office, June 2018

Subject(s):

Drug Costs
Economics, Pharmaceutical
Pharmacies -- economics
Contract Services
United States
United States. Health Resources and Services Administration

25. Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:

Washington, DC : United States Government Accountability Office, July 11, 2018

Subject(s):

Drug Costs
Economics, Pharmaceutical
Pharmacies -- economics
Contract Services
Government Regulation
United States
United States. Health Resources and Services Administration

26. How will the Medicare Part D benefit change under current law and leading proposals?

Author(s):

Cubanski, Juliette, author
Neuman, Tricia, author

Publication:

San Francisco, CA : Henry J. Kaiser Family Foundation, October 2019

Subject(s):

Medicare Part D -- economics
Drug Costs
United States

27. What’s the latest on Medicare drug price negotiations?

Author(s):

Cubanski, Juliette, author
Neuman, Tricia, author
True, Sarah, author
Freed, Meredith, author

Publication:

San Francisco, CA : Henry J. Kaiser Family Foundation, October 2019

Subject(s):

Drug Costs
Medicare Part D -- economics
United States

28. Examining two approaches to U.S. drug pricing: international prices and therapeutic equivalency

Publication:

Washington, D.C. : Bipartisan Policy Center, October 2019

Subject(s):

Costs and Cost Analysis
Drug Costs
Insurance, Health, Reimbursement
Therapeutic Equivalency
Europe
United States

29. Alternative pricing models for remdesivir and other potential treatments for COVID-19

Author(s):

Whittington, Melanie D., author
Campbell, Jonathan D., author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 24, 2020

Subject(s):

Antiviral Agents -- economics
Coronavirus Infections -- drug therapy
Drug Costs
Models, Economic
Pandemics
Pneumonia, Viral -- drug therapy
United States

30. How to strengthen the Medicaid Drug Rebate Program to address rising Medicaid prescription drug costs

Author(s):

Park, Edwin, author

Publication:

Washington, DC : Georgetown University Health Policy Institute, Center for Children and Families, January 2019

Subject(s):

Drug Costs
Medicaid -- economics
United States

31. How Medicaid and CHIP shield children from the rising costs of prescription drugs

Author(s):

Hoadley, Jack, author
Alker, Joan, author

Publication:

Washington, DC : Georgetown University Health Policy Institute, Center for Children and Families, July 2017

Subject(s):

Drug Costs
Insurance Coverage
Insurance, Pharmaceutical Services
Medicaid
Child
United States
State Children's Health Insurance Program (U.S.)

32. What's the latest on Medicare drug price negotiations?

Author(s):

Cubanski, Juliette, author
Neuman, Tricia, author
True, Sarah, author
Freed, Meredith, author

Publication:

[San Francisco, California] : Henry J. Kaiser Family Foundation, July 2019

Subject(s):

Drug Costs
Medicare -- economics
Negotiating
Prospective Payment System
United States

33. Making drug costs more transparent to consumers: a summary for policymakers

Publication:

Oakland, Calif. : California HealthCare Foundation, [2008]

Subject(s):

Community Participation
Disclosure
Drug Costs
Information Services
California
United States

34. Strategic analysis & intelligence (SAI) report: the tier 4 phenomenon : shifting the high cost of drugs to consumers

Publication:

Washington, D.C. : AARP, [2009]

Subject(s):

Cost Sharing
Deductibles and Coinsurance
Drug Costs
Formularies as Topic
United States

35. Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs

Author(s):

Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, March 2017

Subject(s):

Drug Costs
Insurance Coverage
Medicare Part D -- economics
United States
United States.

36. Reducing potential overuse of dementia drugs could lead to considerable savings

Author(s):

Carter, Elizabeth A., author
Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, August 2018

Subject(s):

Dementia -- drug therapy
Dementia -- economics
Drug Costs
Inappropriate Prescribing -- economics
United States

37. The rising cost of specialty drugs drove spending increases for people with multiple sclerosis

Author(s):

Johnson, Bill, author

Publication:

Washington, DC : Health Care Cost Institute, April 2018

Subject(s):

Drug Costs
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Multiple Sclerosis -- economics
Multiple Sclerosis -- drug therapy
United States

38. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters

Publication:

Washington, DC : United States Government Accountability Office, November 2017

Subject(s):

Drug Costs
Drug Industry -- economics
Economics, Pharmaceutical -- trends
Pharmaceutical Research -- economics
Pharmaceutical Research -- trends
United States
National Institutes of Health (U.S.)

39. Medicare Part B: Medicare represented at least half of the market for 22 of the 84 most expensive drugs in 2015 : report to Congressional requesters

Publication:

Washington, DC : United States Government Accountability Office, December 2017

Subject(s):

Drug Costs
Health Care Sector
Health Expenditures
Medicare Part B -- economics
United States

40. Prescription drugs in Nebraska: a survey of experiences and opinions

Publication:

Washington, D.C. : AARP Knowledge Management, c2005

Subject(s):

Data Collection
Drug Costs
Drug Prescriptions -- economics
Pharmaceutical Preparations -- economics
Nebraska
United States

41. Prescription drugs and Medicare Part D: a report on access, satisfaction, and cost

Publication:

Washington, D.C. : AARP Knowledge Management, c2007

Subject(s):

Drug Costs
Drug Prescriptions -- economics
Health Services Accessibility
Medicare Part D
Patient Satisfaction
United States

42. How prescription drug use affects health care utilization and spending by older Americans: a review of the literature

Publication:

Washington, D.C. : AARP Public Policy Institute, c2008

Subject(s):

Delivery of Health Care -- statistics & numerical data
Drug Costs
Drug Prescriptions -- economics
Health Care Costs
Health Expenditures
Insurance, Pharmaceutical Services
United States

43. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

Author(s):

Whittington, Melanie D., author
Campbell, Jonathan D., author
Richardson, Marina, author
Nhan, Emily, author
McKenna, Avery, author
Agboola, Foluso, author
Pearson, Steven D., author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2022

Subject(s):

Ambulatory Care -- economics
Antiviral Agents -- economics
COVID-19 Drug Treatment
Drug Combinations
Drug Costs
Lactams
Leucine
Nitriles
Proline
Ritonavir
United States

44. Medicare Part B drug payments: impact of price substitutions based on 2020 average sales prices

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2022

Subject(s):

Data Analysis
Drug Costs
Government Regulation
Medicare Part B
United States

45. CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022

Subject(s):

Cost Control
Drug Costs
Drug Industry
Government Regulation
Medicare Part B
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)

46. Manufacturers may need additional guidance to ensure consistent calculations of average sales prices

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022

Subject(s):

Drug Costs
Drug Industry
Government Regulation
Medicaid
Medicare Part B
Prescription Fees
United States

47. Medicare Part B drug payments: impact of price substitutions based on 2021 average sales prices

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, August 2023

Subject(s):

Cost Control
Drug Costs
Government Regulation
Medicare Part B
Prescription Fees
United States

48. Technical assistance brief: implementation of inflation-indexed rebates for Part B drugs

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, February 2023

Subject(s):

Drug Costs
Government Regulation
Inflation, Economic
Medicare Part B
United States

49. Fact sheet. The 340B Drug Pricing Program

Publication:

[Washington, D.C.] : American Hospital Association, March 2023

Subject(s):

Drug Costs
Economics, Hospital
Medicare -- economics
United States
340B Drug Pricing Program (U.S.)

50. Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters

Publication:

Washington, DC : United States Government Accountability Office, September 2023

Subject(s):

Drug Costs
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)

51. State biosimilar substitution laws could reduce consumer access and savings

Author(s):

Purvis, Leigh, author
McSpadden, James, author

Publication:

Washington, DC : AARP Public Policy Institute, October 2022

Subject(s):

Biosimilar Pharmaceuticals
Cost Savings
Health Services Accessibility
Legislation, Drug
Drug Costs
State Government
United States

52. Report on the affordability of insulin

Author(s):

Finegold, Kenneth, 1957- author
Sayed, Bisma A., author

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, December 16, 2022

Subject(s):

Costs and Cost Analysis
Drug Costs
Health Expenditures
Insulin -- economics
Diabetes Mellitus -- drug therapy
Diabetes Mellitus -- economics
Medication Adherence
United States

53. Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2019

Subject(s):

Cost Control
Cost Savings
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Reimbursement Mechanisms
United States
Centers for Medicare & Medicaid Services (U.S.)

54. What can the United States learn from pharmaceutical spending controls in France?

Author(s):

Rodwin, March A., author

Publication:

[New York, N.Y.] : The Commonwealth Fund, November 2019

Subject(s):

Cost Control
Drug Costs
Health Expenditures
France
United States
European Union.

55. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents

Author(s):

Doshi, Jalpa A., author
Li, Bengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Armstrong, Katrina A., author

Publication:

Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018

Subject(s):

Antineoplastic Agents -- economics
Antineoplastic Agents -- therapeutic use
Drug Costs
Financing, Personal -- statistics & numerical data
Assessment of Medication Adherence
United States

56. Getting to the root of high prescription drug prices: drivers and potential solutions

Author(s):

Waxman, Henry, author
Corr, Bill, author
Martin, Kristi, author
Duong, Sophia, author

Publication:

[New York, N.Y.] : Commonwealth Fund, July 2017

Subject(s):

Cost Control
Drug Costs
Health Policy
Prescription Drugs -- economics
United States

57. Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit

Author(s):

Pearson, Steven D., author
Dreitlein, Bill, author
Henshall, Chris, author

Publication:

Boston, MA : Institute for Clinical and Economic Review, March 2016

Subject(s):

Drug Costs
Economics, Pharmaceutical
Insurance, Pharmaceutical Services -- economics
Prospective Payment System
Reimbursement Mechanisms -- economics
United States

58. No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending

Author(s):

Cubanski, Juliette, author
Neuman, Tricia, author
Orgera, Kendal, author
Damico, Anthony, author

Publication:

Menlo Park, CA : Henry J. Kaiser Family Foundation, November 2017

Subject(s):

Drug Costs
Financing, Personal
Health Expenditures
Medicare Part D -- economics
Medicare Part D -- trends
United States

59. The Medicaid Drug Rebate Program: the basics

Publication:

Washington, D.C. : George Washington University, [2009]

Subject(s):

Drug Costs
Economics, Pharmaceutical
Medicaid -- economics
United States
Centers for Medicare & Medicaid Services (U.S.)

60. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia

Author(s):

Doshi, Jalpa A., author
Li, Bengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Kumar, Rishab, author
Weiss, Brendan M., author
Huntington, Scott F., author

Publication:

Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016

Subject(s):

Cost Sharing
Drug Costs
Medicare Part D -- economics
United States